Key result
Intranasal bumetanide matches oral and IV systemic exposure while reducing pharmacokinetic variability versus oral therapy.
Why the study?
Intravenous loop diuretics require venous access and hospital infrastructure, while oral absorption can be unreliable during acute decompensated heart failure, driving interest in alternative ambulatory decongestion strategies like intranasal bumetanide.
Does intranasal bumetanide provide comparable systemic exposure and diuretic efficacy to oral and intravenous administration for heart failure decongestion?
Population
68 healthy participants
Comparison
Intranasal bumetanide vs oral vs intravenous administration
Design
Randomized three-way crossover trial
Follow-up
24 hours
Authors
Loading...
Requires validation in heart failure patients; leaves open role in decongestion before practice change.
Does intranasal bumetanide provide comparable systemic exposure and diuretic efficacy to oral and intravenous administration for heart failure decongestion?
Intranasal bumetanide offers a promising non-invasive approach to outpatient heart failure decongestion with comparable bioavailability to IV and oral routes in healthy volunteers, though clinical trials in HF patients are needed.
Azam et al. (2026) conducted a review in Heart failure (n=68). Intranasal bumetanide vs. Oral and intravenous bumetanide was evaluated on Maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC). Intranasal bumetanide demonstrated systemic exposure comparable to oral and intravenous administration, with similar peak concentrations and area under the curve, and reduced pharmacokinetic variability compared with oral therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: